| Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19 E Villa, R Critelli, S Lasagni, A Melegari, A Curatolo, C Celsa, ... Blood advances 5 (3), 662-673, 2021 | 53 | 2021 |
| Role of vitamin D in liver disease and complications of advanced chronic liver disease F Ravaioli, A Pivetti, L Di Marco, C Chrysanthi, G Frassanito, ... International Journal of Molecular Sciences 23 (16), 9016, 2022 | 19 | 2022 |
| From listing to recovery: a review of nutritional status assessment and management in liver transplant patients F Ravaioli, N De Maria, L Di Marco, A Pivetti, R Casciola, C Ceraso, ... Nutrients 15 (12), 2778, 2023 | 8 | 2023 |
| Feasibility, safety, and outcome of second-line nivolumab/bevacizumab in liver transplant patients with recurrent hepatocellular carcinoma L Di Marco, A Pivetti, FG Foschi, R d’Amico, F Schepis, C Caporali, ... Liver Transplantation 29 (5), 559-563, 2023 | 6 | 2023 |
| Endothelial angiopoietin-2 overexpression in explanted livers identifies subjects at higher risk of recurrence of hepatocellular carcinoma after liver transplantation S Lasagni, F Leonardi, A Pivetti, L Di Marco, F Ravaioli, M Serenari, ... Frontiers in Oncology 12, 960808, 2022 | 4 | 2022 |
| Long-Term SARS-CoV-2 Antibody Seroprevalence in Blood Donors, Italy M Ferrari, L Di Marco, A Pivetti, S Paduano, C Vecchi, V Bernabucci, ... Emerging Infectious Diseases 29 (7), 1479, 2023 | 2 | 2023 |
| Upregulation of the oestrogen target gene SIX1 is associated with higher growth speed and decreased survival in HCV‑positive women with hepatocellular carcinoma RM Critelli, F Milosa, A Romanzi, S Lasagni, G Marcelli, L Di Marco, ... Oncology letters 24 (5), 1-10, 2022 | 2 | 2022 |
| Prognostic significance of hypoxic and metabolic gene profiling in hepatocellular carcinoma F Milosa, RM Critelli, S Lasagni, A Pivetti, L Di Marco, D Romagnoli, ... Liver Cancer International 2 (1), 15-26, 2021 | 1 | 2021 |
| Safety and clinical activity of combination treatment with regorafenib and milciclib in liver transplant patients with hepatocellular carcinoma recurrence. A Pivetti, L Di Marco, L Bristot, F Milosa, RM Critelli, N De Maria, ... Journal of Clinical Oncology 38 (15_suppl), e16634-e16634, 2020 | 1 | 2020 |
| Differential Impact of Tumor Endothelial Angiopoietin-2 and Podoplanin in Lymphatic Endothelial Cells on HCC Outcomes with Tyrosine Kinase Inhibitor Treatment According to Sex S Lasagni, RM Critelli, F Milosa, D Saltini, F Schepis, A Romanzi, F Dituri, ... Biomedicines 12 (7), 1424, 2024 | | 2024 |
| SAT-060 Needle tract seeding of hepatocellular carcinoma after liver transplantation: a single center experience C Sicuro, G Frassanito, L Di Marco, A Pivetti, R Odorizzi, C Guidetti, ... Journal of Hepatology 80, S389-S390, 2024 | | 2024 |
| SAT-490 Competitive risk analysis of spleen stiffness measurement with a spleen-dedicated module (SSM@ 100 Hz) for predicting de-novo HCC occurrence in cACLD patients: a … F Ravaioli, L Colecchia, E Dajti, A Vestito, A Gobbato, F Lami, M Renzulli, ... Journal of Hepatology 80, S399-S400, 2024 | | 2024 |
| OC. 05.1: COMPETITIVE RISK ANALYSIS OF SPLEEN STIFFNESS MEASUREMENT WITH A SPLEEN-DEDICATED MODULE (SSM@ 100HZ) FOR PREDICTING DE-NOVO HCC OCCURRENCE IN CACLD PATIENTS: A … F Ravaioli, L Colecchia, E Dajti, A Gobbato, M Renzulli, M Serenari, ... Digestive and Liver Disease 56, S148-S149, 2024 | | 2024 |
| Competitive Risk Analysis of Spleen Stiffness Measurement with a Spleen-Dedicated Module (SSM@ 100Hz) for Predicting de-novo HCC Occurrence in cACLD Patients: A Prospective 5 … F Ravaioli, L Colecchia, E Dajti, A Vestito, A Gobbato, F Lami, M Renzulli, ... Digestive and Liver Disease 56, S80-S81, 2024 | | 2024 |
| A machine learning enabled score based on large varices predicts 5-and 10-year hepatocellular carcinoma (HCC) development in a 12-year prospective cohort of patients with … S Ascari, R Sardone, F Castellana, F Schepis, V Baldaccini, F Semellini, ... Digestive and Liver Disease 55, S221, 2023 | | 2023 |
| Abstract PO003: Combination therapy with Nivolumab/Bevacizumab is safe and effective in patients with recurrent hepatocellular carcinoma after liver transplant L Di Marco, A Pivetti, N De Maria, FG Foschi, D Romagnoli, F Casari, ... Clinical Cancer Research 28 (17_Supplement), PO003-PO003, 2022 | | 2022 |
| Recurrence of hepatocellular carcinoma and hepatitis delta infection in a liver transplant recipient: a case report N Gualandi, G Ciusa, G Dolci, M Tutone, A Pivetti, L Di Marco, GP Guerrini, ... Digestive and Liver Disease 54, S53, 2022 | | 2022 |
| Neoangiogenic transcriptomic signature identifies HCCs with worse response to treatment: long-term results of a prospective study A Pivetti, A Borghi, R Critelli, B Lei, F Casari, M Del Buono, F Milosa, ... Digestive and Liver Disease 52, e11-e12, 2020 | | 2020 |
| Long-term prospective study of development of hepatocellular carcinoma in compensated cirrhosis A Pivetti, P Todesca, V Bernabucci, B Lei, M Del Buono, L Turco, ... Digestive and Liver Disease 52, e61, 2020 | | 2020 |
| Il paziente psoriasico in terapia con farmaci biologici: gestione dei rischi in caso di necessità di un trattamento chirurgico. A PIVETTI | | 2014 |
